Infinity Pharmaceuticals | INFI - Current Liabilities


Infinity Pharmaceuticals reported $12.06M in Current Liabilities for its fiscal quarter ending in June of 2023.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Cipla INR 62.97B 8.13B Sep/2025
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.57M 2.29M Dec/2025
CSL USD 4.61B 207M Dec/2025
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Grifols EUR 2.37B 156.97M Dec/2025
Incyte USD 1.49B 25.52M Mar/2026
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Ionis Pharmaceuticals USD 717M 66M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Plus Therapeutics USD 7.96M 4.36M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
TG Therapeutics USD 187.11M 33.35M Mar/2026